Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Kitko and Patel Emphasize the Importance of GVHD Research and Awareness
Fox Chase Cancer Center and Temple University Hospital Recertified Under ASCO’s Quality Oncology Practice Initiative
Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
European Urology Names Fox Chase Cancer Center’s Dr. Andres F. Correa Reviewer of the Month
Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma